Active Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The Department of Health and Human Services is seeking to renew the licensing fee for the B-hIL2RA transgenic mouse strain, which is crucial for pre-clinical research in photoimmunotherapy targeting IL2RA-expressing Tregs. This model is essential for evaluating treatment materials intended for human application.
The MIB is conducting pre-clinical research on photoimmunotherapy (PIT), a targeted treatment approach that uses light activation to destroy specific cells. One area of this research focuses on IL2RA, a protein expressed on regulatory T cells (Tregs). These cells can reduce the immune system’s ability to respond effectively to cancer. The objective of this work is to selectively eliminate IL2RA-expressing Tregs in order to improve anti-cancer immune responses.
To support this research, MIB uses a transgenic mouse strain known as B-hIL2RA, which expresses the human form of IL2RA rather than the mouse form. Use of this model is essential because it enables evaluation of the same treatment materials, including antibodies, that are intended for future human application. As a result, this mouse strain has proven invaluable in the MIB’s ongoing research program.
The MIB is requesting to renew a licensing fee for transgenic mice, B-hIL2RA. B-hIL2RA transgenic mice.
RENEWAL OF LICENSING FEE FOR THE TRANSGENIC MOUSE STRAIN, B-HIL2RA is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.